Type II Diabetes Mellitus Clinical Trial
— MI-SMSOfficial title:
The Impact of a Motivational Interviewing (MI) Informed Text Messaging (SMS) Program Tailored to Level of Patient Activation on Glycemic Control in a Population of Poorly Controlled Diabetic Patients.
Verified date | February 2018 |
Source | University of Pennsylvania |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Despite advances in medical therapy for diabetes, significant numbers of patients fail to
achieve adequate blood glucose control. Diabetic patients who engage in more self-care
behaviors have better glycemic control, as measured by HbA1C. Patient "activation", defined
as the knowledge, skills, beliefs, and behaviors to manage a chronic disease, is key to the
performance of these self-care behaviors.
There is a growing literature on diabetes behavioral change interventions; however
interventions are often developed and implemented without consideration of patients readiness
to engage in lifestyle changes. Additionally, patient-tailored interventions require
intensive clinical and financial resources, making them difficult to integrate into clinical
practice. Mobile text messaging (SMS) programs have been successfully used to promote smoking
cessation, alcohol cessation, and weight loss in diverse patient populations. SMS
interventions for diabetes have also been developed, but they have been designed primarily to
provide feedback on blood glucose management, rather than to motivate behavioral change. The
few studies that included motivational content as a primary feature, did not tailor their
intervention to a patient's readiness for change or rigorously describe their motivational
intervention, and show limited efficacy.
To address these concerns, we will perform a three-month randomized controlled pilot study to
develop and test a Motivational Interviewing (MI)-informed SMS intervention tailored to
patient level of activation for patients with poorly controlled type II diabetes.
Status | Completed |
Enrollment | 54 |
Est. completion date | December 2014 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - age 18 or older - type II diabetes - poorly controlled diabetes (HbA1C >8 x 2 measurements, with goal < 8) Exclusion Criteria: - pregnancy - non-English speaking or reading |
Country | Name | City | State |
---|---|---|---|
United States | University of Pennsylvania Hospital | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pennsylvania | Center for Healthcare Improvement and Patient Safety, Leonard Davis Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Summary of Diabetes Self-Care Activities | 3 months | ||
Primary | hemoglobin A1C | three months | ||
Secondary | PAM scale | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01952535 -
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01196728 -
Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes
|
Phase 1 | |
Terminated |
NCT00997152 -
Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients
|
Phase 2 | |
Completed |
NCT02592421 -
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
|
Phase 3 | |
Completed |
NCT05544214 -
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01969084 -
The Effect of Linagliptin on Mitochondrial and Endothelial Function
|
Phase 4 | |
Terminated |
NCT01644201 -
A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics
|
Phase 3 | |
Completed |
NCT00995787 -
Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea
|
Phase 1 | |
Completed |
NCT01020123 -
Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients
|
Phase 2 | |
Completed |
NCT01505426 -
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients
|
Phase 3 | |
Completed |
NCT01262586 -
Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.
|
Phase 3 | |
Completed |
NCT00561171 -
Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria
|
Phase 2 | |
Active, not recruiting |
NCT03912363 -
Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids
|
N/A | |
Completed |
NCT01868646 -
Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus
|
Phase 4 | |
Active, not recruiting |
NCT06386328 -
A Clinical Trial to Evaluate the Food Effect of CKD-378
|
Phase 1 | |
Terminated |
NCT02749435 -
A Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus
|
N/A | |
Completed |
NCT00894868 -
Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure
|
Phase 4 | |
Recruiting |
NCT01165190 -
Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans
|
N/A | |
Completed |
NCT01255085 -
Yellow Pea Protein and Fibre and Short Term Food Intake
|
N/A | |
Completed |
NCT02156349 -
A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.
|
N/A |